2026 WAGO Annual Meeting
Sponsors

AbbVie’s mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people’s lives.

We’ve been unlocking the potential of cortisol modulation for more than 25 years.

We’re leading the way in the research and development of cortisol modulators, molecules that regulate cortisol activity at the glucocorticoid receptor (GR). To date, we have discovered more than 1,000 selective proprietary cortisol modulators.

In 2012, we received FDA approval of Korlym® (mifepristone), the first approved treatment for hypercortisolism (Cushing syndrome).

Today, our team and collaborators continue to unlock the possibilities of cortisol modulation as a way to treat serious diseases. With more than 30 ongoing studies across a wide range of disease areas, including endocrinology, oncology, metabolism, and neurology, we remain dedicated to advance the possibilities of cortisol modulation.

What began as a ripple of scientific truth is now poised to unleash a sea change of discovery representing a fundamental shift in the way we understand and treat disease.

Pfizer’s purpose is breakthroughs that change patients’ lives. We pursue that goal relentlessly and innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.

Gilead and Kite Oncology are creating the future of oncology. Making bold strides against cancer requires a strategy built on the power of partnerships, groundbreaking technologies and unexpected clinical combinations. We have purposefully built our pipeline with a focus on depth and breadth to address the greatest unmet needs. From antibody-drug conjugates and small molecules to cell therapy-based approaches, our research and development programs are creating possibilities for people with overlooked, underserved, and difficult-to-treat cancers. We are focused on helping to bring more life to people with cancer and changing the way cancer is treated.

GSK is focused on maximizing patient survival through transformational medicines. GSK’s oncology pipeline is focused on immuno-oncology, cell therapy, cancer epigenetics and synthetic lethality. Our goal is to achieve a sustainable flow of new treatments based on a diversified portfolio of investigational medicines utilizing modalities such as small molecules, antibodies, antibody drug conjugates and cells, either alone or in combination.

Our Company

Unlocking the power of what science cando for people, society and the planet.

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to accelerating the delivery of life-changing medicines that create enduring value for patients, society, the planet and our shareholders.

Our purpose: We use the power of leading-edge science to save and improve lives around the world
For more than 130 years, we’ve brought hope to humanity through the development of important medicines and vaccines. We foster an inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities.

Natera™ is a global leader in cell-free DNA (cfDNA) testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives.